Figure 5
Analysis of hematopoietic stem and progenitor subsets in JAK2-Ex12 transgenic mice. (A) Bar graphs shows the average frequency of LT-HSC (Lin−Kit+Sca-1+CD150+CD48−), ST-HSC (Lin−Kit+Sca-1+CD150+CD48+), MPP (Lin−Kit+Sca-1+CD150lo CD48+), and LSK in total BM (left) and spleen (right) of indicated mice (n = 5-6 mice per each genotype). (B) Average frequency of myeloid precursors LK, CMP (Lin−Kit+Sca-1+ CD34+ FcγRII/IIIlo), GMP (Lin−Kit+Sca-1+ CD34+ FcγRII/III+), and MEP (Lin−Kit+Sca-1+ CD34− FcγRII/IIIlo) in total BM (left) and spleen (right) of indicated mice (n = 5-6 mice per each genotype). (C) Average frequency of MK and erythroid committed subsets, Pre-GM (Lin−Kit+Sca-1−CD41−/+CD150−CD105−), Pre-MegE (Lin−Kit+Sca-1−CD41−/+ CD150+CD105−), MkP (Lin−Kit+Sca-1−CD41+CD150+), Pre–erythroid CFU (CFU-E) (Lin−Kit+Sca-1−CD41−CD150+CD105+), and CFU-E (Lin−Kit+Sca-1−CD41−CD150loCD105+) in total BM (left) and spleen (right) of indicated mice (n = 5-6 mice per each genotype). Mice were analyzed 16 weeks after pIpC injection. (D) Analysis of colonies grown in semisolid media. Numbers on Y-axis indicate the colony counts. (E) Serum Epo levels. (F) Plasma Tpo levels (n = 6 mice per genotype). All data are presented as mean ± SEM. One-way or two-way ANOVA with subsequent Bonferroni post-test was used. *P < .05; **P < .01; ***P < .001. CMP, common myeloid progenitors; GMP, granulocyte-monocyte progenitors; HSC, hematopoietic stem cell; LK, Lin−cKit+; LSK, Lin−Sca-1+cKit+; LT-HSC, long-term HSC; MEP, MK-erythrocyte progenitors; MkP, MK progenitors; MPP, multipotent progenitors; Pre-GM, pre–granulocyte-monocyte progenitors; Pre-MegE, Pre–megakaryocyte-erythroid progenitors; ST-HSC, short-term HSC.

Analysis of hematopoietic stem and progenitor subsets in JAK2-Ex12 transgenic mice. (A) Bar graphs shows the average frequency of LT-HSC (LinKit+Sca-1+CD150+CD48), ST-HSC (LinKit+Sca-1+CD150+CD48+), MPP (LinKit+Sca-1+CD150lo CD48+), and LSK in total BM (left) and spleen (right) of indicated mice (n = 5-6 mice per each genotype). (B) Average frequency of myeloid precursors LK, CMP (LinKit+Sca-1+ CD34+ FcγRII/IIIlo), GMP (LinKit+Sca-1+ CD34+ FcγRII/III+), and MEP (LinKit+Sca-1+ CD34 FcγRII/IIIlo) in total BM (left) and spleen (right) of indicated mice (n = 5-6 mice per each genotype). (C) Average frequency of MK and erythroid committed subsets, Pre-GM (LinKit+Sca-1CD41−/+CD150CD105), Pre-MegE (LinKit+Sca-1CD41−/+ CD150+CD105), MkP (LinKit+Sca-1CD41+CD150+), Pre–erythroid CFU (CFU-E) (LinKit+Sca-1CD41CD150+CD105+), and CFU-E (LinKit+Sca-1CD41CD150loCD105+) in total BM (left) and spleen (right) of indicated mice (n = 5-6 mice per each genotype). Mice were analyzed 16 weeks after pIpC injection. (D) Analysis of colonies grown in semisolid media. Numbers on Y-axis indicate the colony counts. (E) Serum Epo levels. (F) Plasma Tpo levels (n = 6 mice per genotype). All data are presented as mean ± SEM. One-way or two-way ANOVA with subsequent Bonferroni post-test was used. *P < .05; **P < .01; ***P < .001. CMP, common myeloid progenitors; GMP, granulocyte-monocyte progenitors; HSC, hematopoietic stem cell; LK, LincKit+; LSK, LinSca-1+cKit+; LT-HSC, long-term HSC; MEP, MK-erythrocyte progenitors; MkP, MK progenitors; MPP, multipotent progenitors; Pre-GM, pre–granulocyte-monocyte progenitors; Pre-MegE, Pre–megakaryocyte-erythroid progenitors; ST-HSC, short-term HSC.

Close Modal

or Create an Account

Close Modal
Close Modal